SynthesisJournal of the American College of Cardiology2013
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
Synthesis in Journal of the American College of Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design.PharmacoEconomics · 2019Pooled it
- Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.Clinical journal of the American Society of Nephrology : CJASN · 2015 · on this mapPooled it
- Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.Kidney international · 2019Trial
- Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).American journal of kidney diseases : the official journal of the National Kidney Foundation · 2016 · on this mapTrial
- Association between statin therapy as primary prevention and mortality in adults 50 years and older with chronic kidney disease without other indications.Scandinavian journal of primary health care · 2026Article
- Sparsentan for the Treatment of Immunoglobulin A Nephropathy: An Innovative Concept for Economic Modelling.Journal of clinical medicine · 2026Article
- Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective.BMJ public health · 2025Article
- Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China.Advances in therapy · 2024Article
- Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.Cardiovascular diabetology · 2023Article
- Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.Journal of general internal medicine · 2022Article
- Detection of statin-induced rhabdomyolysis and muscular related adverse events through data mining technique.BMC medical informatics and decision making · 2022Article
- Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.Clinical drug investigation · 2022Article
- Long-term health outcomes of people with reduced kidney function in the UK: A modelling study using population health data.PLoS medicine · 2020Article
- Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study.Journal of managed care & specialty pharmacy · 2019Article
- Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States.Patient preference and adherence · 2019Article
- Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.Molecular diagnosis & therapy · 2018Article
- Review
- A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention.Molecular diagnosis & therapy · 2018Article
- Article
- Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.JAMA cardiology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesThe authors sought to evaluate the cost-effectiveness of statins for primary prevention of myocardial infarction (MI) and stroke in patients with chronic kidney disease (CKD).
backgroundPatients with CKD have an elevated risk of MI and stroke. Although HMG Co-A reductase inhibitors (“statins”) may prevent cardiovascular events in patients with non–dialysis-requiring CKD, adverse drug effects and competing risks could materially influence net effects and clinical decision-making.
methodsWe developed a decision-analytic model of CKD and cardiovascular disease (CVD) to determine the cost-effectiveness of low-cost generic statins for primary CVD prevention in men and women with hypertension and mild-to-moderate CKD. Outcomes included MI and stroke rates, discounted quality-adjusted life years (QALYs) and lifetime costs (2010 USD), and incremental cost-effectiveness ratios.
resultsFor 65-year-old men with moderate hypertension and mild-to-moderate CKD, statins reduced the combined rate of MI and stroke, yielded 0.10 QALYs, and increased costs by $1,800 ($18,000 per QALY gained). For patients with lower baseline cardiovascular risks, health and economic benefits were smaller; for 65-year-old women, statins yielded 0.06 QALYs and increased costs by $1,900 ($33,400 per QALY gained). Results were sensitive to rates of rhabdomyolysis and drug costs. Statins are less cost-effective when obtained at average retail prices, particularly in patients at lower CVD risk.
conclusionsAlthough statins reduce absolute CVD risk in patients with CKD, the increased risk of rhabdomyolysis, and competing risks associated with progressive CKD, partly offset these gains. Low-cost generic statins appear cost-effective for primary prevention of CVD in patients with mild-to-moderate CKD and hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.